iPSC-based treatment of age-related macular degeneration (AMD):The path to success requires more than blind faith  

作　　者：Fei Li Jim Hu Tong-Chuan He 

机构地区：[1]The Editorial Office of Genes&Diseases,Chongqing Medical University,Chongqing,400046,China [2]Department of Pathology and Laboratory Medicine,The Hospital for Sick Children,University of Toronto,Toronto,Ontario M5G 0A4,Canada [3]Molecular Oncology Laboratory,Department of Orthopaedic Surgery and Rehabilitation Medicine,The University of Chicago Medical Center,Chicago,IL 60637,USA

出　　处：《Genes & Diseases》2017年第2期41-42,共2页基因与疾病（英文）

基　　金：Work in the authors’laboratories was supported in part by research grants from the National Institutes of Health(AT004418 to TCH);from the Canadian Institutes of Health Research(MOP 125882 to JH);a Cystic Fibrosis Foundation Therapeutics,Inc.grant(HU15XX0 to JH);a Cystic Fibrosis Canada grant(#3032 to JH).

摘　　要：Induced pluripotent stem cells(iPSCs)hold great promise for the treatment of human diseases.Two recent first-of-its-kind clinical case reports on the iPSC-based treatment of age-related macular degeneration(AMD)highlight the hopes and challenges associated with the clinical application of iPSCs.

关 键 词：Autologous iPSC Human Macular degeneration Retinal pigment epithelium Transplantation 

分 类 号：TP3[自动化与计算机技术—计算机科学与技术]